Although ARID1A inactivation and PI3K/AKT pathway alteration frequently occur in CCA, the effect of PI3K or AKT inhibitor has not been well-defined in ARID1A-deficient CCA. This evidence concerns the gene AKT1 and cholangiocarcinoma.